The Tamesis
It is expected to launch 26 new pipeline agents to support its growth.
GlobalData says the age-related macular degeneration (AMD) market across seven major markets (7MM) is expected to grow to $2.05 billion by 2034.
The industry’s expansion has been attributed to the entry of longer-duration therapies, new mechanisms of action, the availability of geographical atrophy (GA) therapies, and the launch of the first early-stage AMD therapy.
Furthermore, the launch of 26 new pipeline agents along with the growing number of AMDs is expected to support the market growth during the forecast period.
Meanwhile, GA’s late-stage development pipeline includes 12 therapies in the 7MM range.
“These late-stage pipeline candidates have huge advantages in the AMD space,” said Sara Reci, MS, pharmaceutical management analyst at GlobalData.
However, treatments are expected to lose market exclusivity, leading to the entry of biosimilars.
Reci added: “Nevertheless, the launch of late-stage pipeline therapies with novel mechanisms of action, routes of administration, longer treatment intervals and improved efficacy will undoubtedly be a driver of market growth in the AMD space.”
7MM = United States, France, Germany, Italy, Spain, United Kingdom and Japan
